Skip to main content

CGAM Hero

BRINGING

YOUR

SCIENCE

TO LIFE

homepageheroesv22-1_page-0001.jpeg
homepageheroesv22-2_page-0001.jpeg
homepageheroesv23-InterviewwithJeroendeJongManagerRiskCompliance.jpeg
previous arrow
next arrow

LATEST NEWS

  • CARBOGEN AMCIS Manchester wins prestigious Chemical Industry Award for world-class manufacturing performance

    CARBOGEN AMCIS Manchester wins prestigious Chemical Industry Award for world-class manufacturing performance

    CARBOGEN AMCIS Manchester wins prestigious Chemical Industry Award for world-class manufacturing performance

    Manchester, UK (20 June 2023) – CARBOGEN AMCIS Manchester, a member of the Switzerland-based CARBOGEN AMCIS Group, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, won the Manufacturing and Resource Efficiency Award at the prestigious Chemistry Industry Awards last week.

    CARBOGEN AMCIS Manchester won the industry award in recognition of its efficiency improvement program implemented in response to...

  • CARBOGEN AMCIS announces successful FDA and Swissmedic inspections of its facilities in Switzerland

    CARBOGEN AMCIS announces successful FDA and Swissmedic inspections of its facilities in Switzerland

    CARBOGEN AMCIS announces successful FDA and Swissmedic inspections of its facilities in Switzerland

    BUBENDORF, Switzerland (02 june 2023) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the completion of a U.S. Food and Drug Administration (FDA) inspection at its headquarters in Bubendorf, Switzerland and a Swissmedic routine inspection at Bubendorf, Aarau and Neuland, Switzerland.

    From December 8th - 16th 2022, a seven-day surveillance...

  • CARBOGEN AMCIS opens new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in France

    CARBOGEN AMCIS opens new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in France

    CARBOGEN AMCIS opens new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in France

    Bubendorf, Switzerland (3 February 2023) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has opened a state-of-the-art facility in Saint-Beauzire, France.

    The new site is dedicated to the custom development and production of sterile injectable drug products. Built on newly acquired land located 7km from an existing CARBOGEN AMCIS site in Riom, the new facility increases product...

  • CARBOGEN AMCIS announces successful Swissmedic inspection at Vionnaz, Switzerland

    CARBOGEN AMCIS announces successful Swissmedic inspection at Vionnaz, Switzerland

    CARBOGEN AMCIS announces successful Swissmedic inspection at Vionnaz, Switzerland

    Bubendorf, Switzerland (Septembre 29, 2022) – Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced that its site in Vionnaz, Switzerland has successfully completed a Swissmedic inspection performed by Regional Medicines Inspectorate of Western Switzerland (ISOPTh).

    The two-day inspection took place from September 20th to 21th, 2022 and was undertaken by an inspector of Regional Medicines Inspectorate of Western Switzerland...

  • CARBOGEN AMCIS appointed new Vice President of Business Development, Sales & Marketing

    CARBOGEN AMCIS appointed new Vice President of Business Development, Sales & Marketing

    CARBOGEN AMCIS appointed new Vice President of Business Development, Sales & Marketing

    BUBENDORF, Switzerland (July 21, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today the appointment of François Baduel as Vice President of Business Development, Sales & Marketing.

    In his new role, François Baduel will lead the company’s overall sales and marketing operations. He will report directly to Pascal Villemagne, Chief Executive Officer,...

  • Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

    Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

    Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

    BUBENDORF, Switzerland (March 31, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces that Pascal Villemagne has been named Chief Executive Officer, effective first of April

    In his new role, Pascal Villemagne will be leading CARBOGEN AMCIS and its nine sites around the world. He will report to Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd., CARBOGEN AMCIS’ parent company. Villemagne, who has served as Vice President of Sales...

  • Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

    Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

    Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

    Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Limited, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood lymphocyte...

  • NH TherAguix announces the release of a new clinical batch for its drug AGuIX, manufactured by CARBOGEN AMCIS

    NH TherAguix announces the release of a new clinical batch for its drug AGuIX, manufactured by CARBOGEN AMCIS

    NH TherAguix announces the release of a new clinical batch for its drug AGuIX, manufactured by CARBOGEN AMCIS

    MEYLAN, France, BUBENDORF, Switzerland, (November 3rd, 2021) - NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and Drug Products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.

    CARBOGEN AMCIS just released the fifth batch of AGuIX Drug Product since inception of the company. The release of this 3.7 kg batch...

  • CARBOGEN AMCIS announces successful FDA inspection of its facility in Aarau, Switzerland

    CARBOGEN AMCIS announces successful FDA inspection of its facility in Aarau, Switzerland

    CARBOGEN AMCIS announces successful FDA inspection of its facility in Aarau, Switzerland

    BUBENDORF, Switzerland (27 October 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the completion of a U.S. Food and Drug Administration (FDA) inspection at the site in Aarau, Switzerland.

    The pre-approval FDA paper inspection for an intermediate product from a customer was conducted from 17 August - 15 September 2021. By receiving the result in October 2021 the inspection was concluded successfully with no findings, confirming that...

  • CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client

    CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client

    CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client

    BUBENDORF, Switzerland (27 Aug 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the signing of a co-investment agreement with one of its key European customers.

    The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and is following a previous investment of CHF 6 million.

    The recent...

  • CARBOGEN AMCIS acquires new property at Bubendorf site

    CARBOGEN AMCIS acquires new property at Bubendorf site

    CARBOGEN AMCIS acquires new property at Bubendorf site

    • English

      BUBENDORF, Switzerland (24 June, 2021) Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced the acquisition of a new property in Bubendorf.  

      CARBOGEN AMCIS confirms the acquisition of further property in Bubendorf (Basel-Landschaft), where the company's headquarters are located. The property in Hauptstrasse 175 has been acquired from the previous owners Marcel und Theres Rutschmann and...

  • CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

    CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

    CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

    BUBENDORF, Switzerland (April 29th, 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today a joint funding agreement with a long standing Japan based customer to build  a site extension at the Bubendorf site in Switzerland.  

    The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will...

    UPCOMING EVENTS

    • BioFIT 2023

      BioFIT 2023

      Marseille, France

      BioFIT 2023

       From to 

       

       

       

       

       

      With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.

    • Zurich Life Science Day

      Zurich Life Science Day

      University of Zurich, Irchel Campus

      Zurich Life Science Day 2024

       From to 

       

       

       

       

       

      Are you passionate about sciences, chemistry or biochemistry? Meet our HR team at the ZLSD, the largest career fair for life sciences in Switzerland. 

      It is a pleaseure for us to show participants different career paths and opportunities to enter the job market. One-to-One meetings also available.

      Contact us if you are attending!

    • DCAT Week 2024

      DCAT Week 2024

      The Benjamin NYC, New York City, NY

      DCAT Week 2024

       From to 

       

       

       

       

       

      DCAT Week is the premier global event held each year in New York City for companies engaged in the Bio/Pharmaceutical manufacturing value chain.

    • BIOMED 2024

      BIOMED 2024

      Tel Aviv, Israel

      BIOMED 2024

       From to 

       

       

       

       

       

      You are invited to attend BIOMED Israel Conference and Exhibition, the leading life sciences conference in Israel. The event has hosted 6,000 industry professionals, including 1,000 international participants from 45 countries. Meet us there and book your one-on-one meeting. 

    • ChemSpec 2024

      ChemSpec 2024

      Messe Düsseldorf, Deutschland

      Chemspec Europe 2024

       From to 

       

       

       

       

       

      The 37th International Exhibition for Fine and Speciality Chemicals will take place from 19 - 20 June 2024, at Messe Düsseldorf, Germany.Chem

      The exhibition showcases the entire spectrum of fine and speciality chemicals for various applications and industries. A first-rate conference programme accompanies the event and offers plenty of additional networking opportunities to exchange industry know-how and form international relations with peers and business partners.

      A global presence with
      9
      sites
      in Switzerland, UK, France, Netherlands & China
      More than
      40
      years
      of experience in clinical API development
      Production from gram to several
      1000
      kilogrammes
      scale manufacturing for API production
      Up to
      8000
      litres
      of capacity for API production

      For more information
      download our Company Profile
      brochure or contact us today.